



**Invitation: Conference Call on 23 May 2022, 10.00 a.m. CEST
presenting Marinomed's Q1 2022 results**

Korneuburg, Austria, 12 May 2022 – Marinomed Biotech AG (VSE:MARI), Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics is pleased to invite you to an international conference call (held in English language) to present its Q1 2022 results. The conference call is scheduled for 10.00 a.m. CEST (9.00 a.m. BST). Your dialogue partners will be Dr. Andreas Grassauer, CEO, and Pascal Schmidt, CFO.

Pre-registration:

Participants may pre-register and will receive dedicated dial-in details to access the call easily and quickly:

<https://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=7120499&linkSecurityString=edc07ac59>

Logging in to the call:

Once registered (see above), please use the information provided in the confirmation email. We recommend dialing in a few minutes prior to the call.

Concurrent presentation:

Slide Show Participants' Link:

<https://www.c-meeting.com/web3/join/MLD3PK2LN4AYV8>

The Marinomed presentation window will open at the beginning of the conference. The webcast does not support audio (please follow the instructions above for audio). The presentation can be downloaded c. 15 minutes before the conference call from the Company's website:

<https://www.marinomed.com/en/investors/publications>

The press release on the Q1 results 2022 will be published at 7.45 a.m. CEST / 6.45 a.m. BST and will be available in the news section of the Company's website: <https://www.marinomed.com/en/news>

If you have any further questions, please do not hesitate to contact:

Stephanie Kniep, Investor Relations

Marinomed Biotech AG

Hovengasse 25, 2100 Korneuburg, Austria

E-Mail: ir@marinomed.com

T: +43 2262 90300 226

International Media Contact

MC Services AG

Dr. Brigitte Keller, Dr. Regina Lutz

T +49 89 210228 0

UK: Shaun Brown

M: +44 7867 515 918

E-Mail: marinomed@mc-services.eu

Disclaimer

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.